Dicerna Pharmaceuticals, Inc. Common Stock, also called Dicerna Pharmaceuticals, is a biopharmaceutical company, which engages in the discovery and development of treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. Read More The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson and John J. Rossi in 2007 and is headquartered in Watertown, MA. The listed name for DRNA is Dicerna Pharmaceuticals, Inc. Common Stock.